Share Prices & Company Research

Stockbroking

Vectura Group

Current Price 0.00p Bid 0.00p Ask 0.00p Change 0.00%
Last Updated: 09/05/2024 03:53. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Vectura develops inhaled therapies principally for the treatment of respiratory diseases. Inhaled formulation development is increasingly complex with a wide variety of small molecules and biologics, increasing use of combination products and the need for targeted lung delivery or deep lung deposition for systemic delivery. We offer formulation services for DPI, pMDI and nebuliser development, including small molecules and biologics, complex combinations and generic products.

Financial Highlights Year Ended 31/12/2020

Revenue
£190.60m
Operating Profit/Loss
£132.80m
Dividend yield (%)
n/a
Total dividend for year
n/ap
Dividend cover
n/a
P/E Ratio
6.10
More Financials

Key Personnel

Mr Will Downie
CEO and Executive director
Mr Paul Fry
CFO & Executive Director
Dr Kevin Matthews
Independent Non-Executive Director
Ms Jeanne Hecht
Independent Non-Executive Director
Ms Jeanne Thoma
Independent Non-Executive Director
Ms Juliet Thompson
Independent Non-Executive Director
Mr Bruno Angelici
Non-Executive Chairman
Dr Per-Olof Andersson
Non-Executive Director

Stock Details

EPIC
VECL
ISIN
GB00B01D1K48
Shares in Issue
410.53m
Market cap
£0.00m

Price Summary

Mid Price
0.00p
Bid Price
0.00p
Ask Price
0.00p
Volume
0
Change Today
0.00p
% Change Today
0.00%
Open
0.00p
Previous Close
0.00p
Intraday High
0.00p
Intraday Low
0.00p
52 Week High
0.00p
52 Week Low
0.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

More Charts

News

Income Statement

Year End Date
31 Dec 2020
31 Dec 2019
 
£ (M)
£ (M)
Continuing Operations
Revenue
190.60
178.30
Operating Profit/Loss
132.80
-27.00
Net Interest
-1.50
0.90
Pre-Tax Profit
131.30
-26.10
Profit After Tax from continuing operations
122.40
-22.10
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
122.40
-22.10
Attributable to:
Equity Holders of Parent Company
122.40
-22.10
Minority Interests
n/a
n/a
Total Dividend Paid
n/ap
n/ap
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2020
31 Dec 2019
Basic
20.50p
-3.40p
Diluted
20.10p
-3.40p
Adjusted
20.50p
-3.40p
Dividend per Share
n/ap
n/ap

Assets

Year End Date
31 Dec 2020
31 Dec 2019
 
£ (M)
£ (M)
Non-Current Assets
Property, Plant & Equipment
56.40
55.10
Intangible Assets
299.70
326.30
Investment Properties
n/a
n/a
Investments
n/a
n/a
Other Financial Assets
n/a
n/a
Other Non-Current Assets
4.30
3.20
Current Assets
Inventories
28.80
27.70
Trade & Other Receivables
198.20
44.30
Cash at Bank & In Hand
78.60
74.10
Current Asset Investments
n/a
n/a
Other Current Assets
n/a
n/a
Other Assets
n/a
n/a
Total Assets
666.00
530.70

Liabilities

Year End Date
31 Dec 2020
31 Dec 2019
 
£ (M)
£ (M)
Current Liabilities
Borrowings
1.20
1.20
Other Current Liabilities
84.00
62.90
Total Current Liabilities
85.20
64.10
Non-Current Liabilities
Borrowings
3.00
6.40
Provisions
31.30
36.30
Other Non-Current Liabilities
2.10
4.50
Total Non-Current Liabilities
36.40
47.20
Other Liabilities
n/a
n/a
Total Liabilities
121.60
111.30

Net Assets

Year End Date
31 Dec 2020
31 Dec 2019
 
£ (M)
£ (M)
Net Assets
544.40
419.40

Capital & Reserves

Year End Date
31 Dec 2020
31 Dec 2019
 
£ (M)
£ (M)
Share Capital
0.20
0.20
Share Premium Account
61.70
61.60
Other Reserves
366.60
350.20
Retained Earnings
115.90
7.40
Shareholders Funds
544.40
419.40
Minority Interests/Other Equity
n/a
n/a
Total Equity
544.40
419.40

Dividend History

Dividend Metrics

Year End Date
31 Dec 2020
31 Dec 2019
Dividend growth
n/a%
n/a%
Dividend yield
n/a%
n/a%
Dividend cover
n/a
n/a


Cboe Global Markets® is a registered trade mark of Cboe Global Markets, Inc., a company incorporated in the United States of America with registered address at 400 South LaSalle Street, Chicago, IL 60605, USA. Cboe shall own any and all rights including without limitation Intellectual Property rights and any and all goodwill arising directly or indirectly out of the Recipient’s use of the “Cboe Global Markets®”, “Cboe®” and “Bats®”” trademarks. Neither Cboe nor its licensors accept any liability for any errors or omissions in the Cboe Europe Indices or underlying data. No further distribution of Cboe Europe data is permitted without Cboe’s express written consent.

The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.